Krishna C Bulusu

Employment

• Turbine AI VP, Product Innovation & Strategy
  2025 - Present
• AstraZeneca UK Limited Director
  2017 - 2025
• University of Cambridge Postdoctoral Research Associate
  2014 - 2017

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (83)

• BEACON: predicting side effects and therapeutics outcomes to drugs by Bridging knowlEdge grAph with CONtextual language model
  2026 DOI: 10.64898/2026.01.29.702277
  +Save
• Bimodality in pan-cancer proteomics reveals new opportunities for biomarker discovery
  2025 DOI: 10.1101/2025.03.03.641218
  +Save
• Table S3 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
  2024 DOI: 10.1158/2159-8290.25729243.v1
  +Save
• Table S13 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
  2024 DOI: 10.1158/2159-8290.25729270.v1
  +Save
• Table S2 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
  2024 DOI: 10.1158/2159-8290.25729246
  +Save
• Table S2 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
  2024 DOI: 10.1158/2159-8290.25729246.v1
  +Save
• Table S18 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
  2024 DOI: 10.1158/2159-8290.25729252
  +Save
• Table S18 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
  2024 DOI: 10.1158/2159-8290.25729252.v1
  +Save
• Table S17 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
  2024 DOI: 10.1158/2159-8290.25729258
  +Save
• Table S16 from Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
  2024 DOI: 10.1158/2159-8290.25729261.v1
  +Save